<<<How big is the probability that DOR gets orBEC approved? >>>
It missed the primary endpoint, blah-blah-blah (although really that is a serious issue).
But then you look at those survival numbers, how could they not approve it ?
<<<Much fantasy, much risk, much potential....>>>
That's biotech - and when you have a lot of the above, your chance should come some time.
"....on the biotech battle-field, you need some élan...."
Market Data 
Markets 
AI
